Li et al. found higher TIM-3 overexpression in CD4+ T-cells from patients with FLT3-mutated compared to non-mutated AML, and in CD8+ cells of high-risk compared to low-risk AML patients [148]. This evidence concerns the gene HAVCR2 and acute myeloid leukemia.